Takeda (TAK) announced new data from two pivotal Phase 3 studies of zasocitinib (TAK-279), its next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The results highlight that once-daily oral zasocitinib achieved rapid and durable skin clearance, with a safety profile consistent with earlier Phase 2b studies.
In the trials, about 70% of patients treated with zasocitinib reached clear or almost clear skin (sPGA 0/1) by week 16. Additionally, a significantly greater PASI 75 response rate compared to placebo was observed as early as week 4, underscoring the drug's potential for fast-acting efficacy.
Takeda confirmed that it remains on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration and other regulatory authorities beginning in fiscal year 2026.
The company also noted that the Phase 3 study results will not have a significant impact on its consolidated forecast for the fiscal year ending March 31, 2026.
TAK closed regular trading at $17.91 on March 27, 2026. The share price slipped by $0.15, representing a decline of 0.83%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.